Insight

Razelle Kurzrock: Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors

Razelle Kurzrock/froedtert.com

Nov 4, 2024, 15:36

Razelle Kurzrock: Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors

Razelle Kurzrock, Associate Director of Clinical Research for the Medical College of Wisconsin Cancer Center, shared a post on X about her recent article published in Journal for ImmunoTherapy of Cancer.

“Young Chae reports Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: desmoid: Journal for ImmunoTherapy of Cancer.”

“Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the desmoid tumors”

Authors: Young Kwang Chae, Megan Othus, Sandip Patel, Charles Blanke, Razelle Kurzrock et al.

More posts featuring Razelle Kurzrock.

Razelle Kurzrock, MD, is a world-renowned physician-scientist leader in precision medicine as well as in the development of novel therapeutics in the field of oncology. She is recognized for founding, developing and chairing one of the largest Phase 1 clinical trial departments globally while at the University of Texas MD Anderson Cancer Center; the central theme of the department was a personalized medicine strategy.

She is also one of the pioneering trialists of the WINTHER precision medicine international trial focusing, for the first time, on transcriptomics in addition to genomics. This trial was the signature study of the Worldwide Innovative Network (WIN) consortium (Nature Medicine). She also developed and led some of the first tumor-agnostic cancer clinical trials.

During her time at the University of California San Diego Health, Dr. Kurzrock’s charge was founding and leading the Center for Personalized Cancer Therapy as well as the Experimental Therapeutics program, and she also founded a Rare Tumor Clinic focused on precision medicine.

The signature study of the center was the I-PREDICT study (Nature Medicine, 2019) that gave, for the first time, individualized N-of-1 matched combination therapies to patients with lethal malignancies, hence resulting in improved outcomes, and transforming the entire paradigm for oncology treatment. This work was presented at the Nobel Symposium, Karolinska Institute, Stockholm, Sweden in September 2023.

Dr Kurzrock has performed key early-phase studies of 8 drugs that have gone on to FDA approval. Many of her studies have also been incorporated into NCCN guidelines.Dr. Kurzrock is also an entrepreneur. She is co-founder of CureMatch, and on the Board of CureMetrix, CureMatch, and Xcures.

Dr. Kurzrock is the author of >1000 peer-reviewed articles on PubMed and has a highly exceptional Hirsch index (h-index) score of 147, with over almost 100,000 citations. She has been selected each year since 2019 as one of the world’s most cited scientists worldwide.

She has four children and three dogs and lives with her husband Philip Cohen, MD.